Daily Ards Research Analysis
Two studies under the umbrella of 'ARDS' address very different domains: a novel multimedia symptom appraisal tool for autoimmune rheumatic diseases (ARDs) showed promising diagnostic screening performance, and a COVID-19 case series of hemoperfusion suggested biomarker improvements without mortality benefit. These works underscore opportunities in digital triage and the limits of extracorporeal cytokine modulation.
Summary
Two studies under the umbrella of 'ARDS' address very different domains: a novel multimedia symptom appraisal tool for autoimmune rheumatic diseases (ARDs) showed promising diagnostic screening performance, and a COVID-19 case series of hemoperfusion suggested biomarker improvements without mortality benefit. These works underscore opportunities in digital triage and the limits of extracorporeal cytokine modulation.
Research Themes
- Digital symptom appraisal and early diagnosis in autoimmune rheumatic diseases
- Extracorporeal immunomodulation (hemoperfusion) in severe COVID-19
- Diagnostic accuracy, reliability, and real-world pilot testing
Selected Articles
1. Development of START, a novel multimedia-based symptom appraisal tool for autoimmune rheumatic diseases.
START is a theory-informed, multimedia symptom appraisal tool for autoimmune rheumatic diseases that distilled 59 manifestations to 19 items via expert consensus and patient cognitive interviews. In a pilot with 145 ARD cases, 133 non-ARD patients, and 155 healthy controls, START achieved 86.2% sensitivity, 80.9% specificity, and good test-retest reliability (0.789).
Impact: Provides a validated, user-centered tool that could shorten diagnostic delay in ARDs and standardize symptom appraisal across settings. Methodological rigor in development and initial psychometrics suggests broad translational potential.
Clinical Implications: START could serve as a frontline digital triage aid to flag suspected ARDs for earlier specialist referral, potentially improving outcomes through timelier diagnosis. It should complement, not replace, clinician assessment and requires external validation in diverse populations.
Key Findings
- Expert consensus reduced 59 manifestations to 19 items with content validity.
- Pilot testing showed sensitivity 86.2% and specificity 80.9% for detecting any ARDs.
- Test-retest reliability was acceptable (0.789), and multimedia visuals improved comprehension.
- Development followed a social cognitive theory-based framework with expert and patient input.
Methodological Strengths
- Theory-driven development with expert consensus and cognitive debriefing
- Prospective pilot across ARD cases, non-ARD patients, and healthy controls with psychometric reporting
Limitations
- Single-stage pilot; lacks external validation across regions and care levels
- Diagnostic accuracy may vary in primary care and non-English or low-literacy settings
Future Directions: Conduct multicenter external validation, assess performance in primary care and diverse languages, evaluate impact on referral times and outcomes, and integrate with EHR/AI-based decision support.
OBJECTIVES: To facilitate earlier diagnosis of autoimmune rheumatic diseases (ARDs), we aimed to (i) develop Symptom Testing for Autoimmune RheumaTic diseases (START), a novel multimedia-based symptom appraisal tool for ARDs and (ii) pilot test START among established ARD cases and non-ARD controls. METHODS: We developed START using a social cognitive theory-based theoretical framework and consensus-based lists of ARDs and manifestations from our previous work. START was revised through reviews by an expert panel of rheumatologists and cognitive debriefing interviews (CDIs) with patients newly referred for assessment of ARDs. We pilot tested START to evaluate its sensitivity, specificity and test-retest reliability in detecting patients with known ARDs. RESULTS: Of the 59 manifestations of ARDs identified from our previous work, 33 reached expert consensus for content validity, 26 were removed because they were non-specific or late features of ARDs. Similar manifestations were grouped, resulting in 19 items. The phrasing and formatting of items in START were revised based on findings from the CDIs with 36 patients and expert panel review. Visual illustrations such as photos and drawings were included to improve comprehension of items in START, using an online platform for implementation. Pilot testing in 145 patients with ARDs, 133 patients with non-ARDs and 155 healthy controls found that the sensitivity, specificity and test-retest reliability in detecting patients with any ARDs were 86.2%, 80.9% and 0.789, respectively. CONCLUSION: A novel multimedia-based symptom appraisal tool for ARDs was developed, which addresses the limitations of existing tools and exhibited promising sensitivity and specificity in detecting patients with known ARDs.
2. Effect of hemoperfusion in critically ill COVID-19 patients: a case series from a single-center hospital in Indonesia.
In a four-patient case series of critically ill COVID-19 treated with HA330 hemoperfusion, only one patient recovered and two completed three sessions. Although inflammatory biomarkers decreased, there was no observed mortality benefit, highlighting the limited clinical impact in this small series.
Impact: Provides real-world data from a low-resource setting on hemoperfusion for cytokine storm, including negative outcomes that help calibrate expectations and future trial design.
Clinical Implications: Hemoperfusion may reduce inflammatory biomarkers in severe COVID-19 but should not be expected to improve survival based on current evidence. Use should be individualized and ideally studied within clinical trials.
Key Findings
- Four critically ill COVID-19 patients received HA330 hemoperfusion as adjunctive therapy.
- Only two patients completed three hemoperfusion cycles; one patient recovered.
- Inflammatory biomarkers decreased, but there was no mortality benefit observed.
Methodological Strengths
- Clear inclusion criteria focusing on organ dysfunction and hyperinflammation
- Use of objective inflammatory biomarkers to assess response
Limitations
- Very small sample size and lack of control group
- Single-center case series; potential selection and survivorship biases
Future Directions: Prospective controlled studies to evaluate patient selection, timing, dosing (number of sessions), and clinically meaningful outcomes beyond biomarkers.
INTRODUCTION: Hemoperfusion (HP), a blood filtration method targeting the removal of toxins and inflammatory elements, was investigated in this study. The objective was to present the observations in four individuals with confirmed COVID-19 who underwent several rounds of HP utilizing the HA330 cartridge at a hospital in Indonesia. CASE STUDIES: We report four cases of COVID-19 patients who underwent HP. The decision to start HP in COVID-19 patients hinges on severe illness and specific indications such as refractory hypercytokinemia or cytokine storm syndrome, despite conventional treatments. Inclusion criteria were evidence of organ dysfunction; particularly the lungs, kidneys, or liver; and significant inflammatory markers or laboratory abnormalities. The four cases described here received HP as a supplementary treatment for COVID-19. However, only two of these patients successfully finished three cycles of HP, and just one exhibited improvement and was eventually declared to have recovered. CONCLUSIONS: The rationale behind HP in COVID-19 patients lies in its potential to mitigate the cytokine storm, a hallmark of severe disease. COVID-19 is known to trigger an excessive inflammatory response, leading to organ damage and respiratory distress. HP, through the use of devices such as the HA330 cartridge, aims to remove inflammatory cytokines and toxins from blood circulation. Utilizing at least three sessions of HA-330 HP in addition to standard treatment in severe COVID-19 demonstrated a beneficial effect on decreasing inflammatory biomarkers, although it did not affect mortality rates.